{"ticker": {"uuid": "20643047-7424-4d8f-896c-c50ad12b7998", "symbol": "AQST", "name": "Aquestive Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Form 144 Aquestive Therapeutics For: 15 July By Investing.com", "summary": "This article from Investing.com announces a Form 144 filing for Aquestive Therapeutics on July 15. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates of Aquestive Therapeutics plan to sell shares. The brief piece provides limi", "url": "https://ca.investing.com/news/stock-market-news/form-144-aquestive-therapeutics-for-15-july-93CH-4736181", "source_name": "Investing.com Canada", "published_at": "2026-07-16T01:45:38", "published_display": "16 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aquestive Therapeutics, Inc. \u2013 NASDAQ:AQST", "summary": "This article provides financial information for Aquestive Therapeutics, Inc. (NASDAQ: AQST), specifically focusing on its forward price-to-earnings ratio. It is presented on TradingView, a platform offering various financial tools and market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T17:45:38", "published_display": "15 Jul 2026 17:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and cont", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180644", "source_name": "ACCESS Newswire", "published_at": "2026-07-14T11:00:00", "published_display": "14 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc (AQST) Institutional Confidence", "summary": "Aquestive Therapeutics Inc (AQST) has an institutional shareholding score of 5.00, placing it 73rd in the Pharmaceuticals industry. Institutional investors collectively hold 60.30% of the company's shares, an increase of 16.75% quarter-over-quarter. Bill Nygren of OAKMX is the la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aqst/sentiment", "source_name": "TradingKey", "published_at": "2026-07-13T13:43:38", "published_display": "13 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST) and its officers. The firm is encouraging shareholders who purchased AQST securities before June 16, 2025, and still hold them, to contact t", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aquestive-therapeutics-inc.-aqst-investigation-bronstein-gewirtz-1180643", "source_name": "ACCESS Newswire", "published_at": "2026-07-13T02:10:30", "published_display": "13 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) concerning possible corporate wrongdoing by its officers and/or directors. The firm encourages investors who purchased Aquestive securities before June 16, 2025, and s", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1180642", "source_name": "ACCESS Newswire", "published_at": "2026-07-10T06:09:40", "published_display": "10 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism", "summary": "Aquestive Therapeutics, a pharmaceutical company, will attend the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14, 2026, where its management team will host 1x1 investor meetings. The forum will focus on key therapeutic themes in immunology, inflammation, and m", "url": "https://investingnews.com/aquestive-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-ii-and-metabolism/", "source_name": "Investing News Network", "published_at": "2026-07-07T12:39:33", "published_display": "07 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) securities who bought prior to June 16, 2025, and still hold them. The investigation focuses on whether Aquestive and its officers/directors engaged", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aquestive-therapeu-1180641", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Aquestive Therapeutics (AQST)", "summary": "This article analyzes the historical performance of an imagined $1,000 investment in Aquestive Therapeutics (AQST) over one, five, and ten-year periods, showing the total returns and compound annual growth rates. It details Aquestive Therapeutics' business model, proprietary tech", "url": "https://www.stocktitan.net/tools/stock-return-calculator/AQST", "source_name": "Stock Titan", "published_at": "2026-07-04T00:09:48", "published_display": "04 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages Aquestive stockholders who purchased securities before June 16, 2025, and still hold them, to contact them for more information and to a", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1180639", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T02:41:21", "published_display": "02 Jul 2026 02:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to a", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aquestive-therapeutics-inc.-aqst-investigation-bronstein-gewirtz-1180638", "source_name": "ACCESS Newswire", "published_at": "2026-06-30T11:00:00", "published_display": "30 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Form S-3 filed by Aquestive Therapeutics Inc.", "summary": "Aquestive Therapeutics Inc. (AQST) filed an S-3 form with the SEC, which was promptly reported by Quantisnow. Quantisnow is a real-time market data and news platform that provides alerts on SEC filings, FDA approvals, analyst ratings, and insider trades to retail investors. The a", "url": "https://www.quantisnow.com/insight/sec-form-s-3-filed-by-aquestive-therapeutics-inc-6617429", "source_name": "Quantisnow", "published_at": "2026-06-27T19:41:22", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on the filing of Form S-3 by Aquestive Therapeutics Inc. on June 26. The brief notice indicates a regulatory filing related to the company, suggesting potential corporate actions such as a stock offering.", "url": "https://ca.investing.com/news/stock-market-news/form-s3-aquestive-therapeutics-inc-for-26-june-93CH-4710049", "source_name": "Investing.com Canada", "published_at": "2026-06-26T20:40:55", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Stock Price and Chart \u2014 NASDAQ:AQST", "summary": "This page provides a comprehensive overview of Aquestive Therapeutics, Inc. (AQST) stock, including its current price, performance across various timeframes, key financial statistics, and upcoming earnings dates. It also features a collection of trading ideas and analyses from th", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:22", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST)", "summary": "This article provides an overview of Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock, including its current price, market capitalization, analyst forecasts, and historical performance. It also details recent financial actuals such as earnings per share and revenue, and forthcom", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:56", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9", "summary": "LifeSci Capital has reiterated its Buy rating for Aquestive Therapeutics (AQST.US) and maintained its target price at $9. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72051602/lifesci-capital-maintains-aquestive-therapeutics-aqstus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T01:12:46", "published_display": "26 Jun 2026 01:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether the company's officers and/or directo", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-aquestive-therapeutics-inc-aqst", "source_name": "The National Law Review", "published_at": "2026-06-25T15:10:52", "published_display": "25 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Aquestive Therapeutics Inc. submitted on June 24th. The filing indicates insider transactions for the company (AQST). The article provides no further details beyond the existence of the filing and some financial data unrelated to the sp", "url": "https://ng.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-for-24-june-93CH-2572473", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T06:12:46", "published_display": "25 Jun 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com", "summary": "Aquestive Therapeutics director Julie Krop sold $125,392 worth of company stock, involving 25,000 shares at $5.0157 per share, following the exercise of stock options. The sale was executed under a Rule 10b5-1 trading plan, occurring after the stock saw a 57% surge over the past ", "url": "https://ca.investing.com/news/stock-market-news/aquestive-therapeutics-director-julie-krop-sells-125k-in-stock-93CH-4705776", "source_name": "Investing.com Canada", "published_at": "2026-06-24T15:41:05", "published_display": "24 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?", "summary": "Aquestive Therapeutics (AQST) saw a 6.6% stock rally, closing at $5.03, driven by investor confidence in its lead product candidate, Anaphylm, and its development pipeline. The company plans to resubmit its NDA for Anaphylm in Q3 2026 and is also advancing AQST-108. Despite robus", "url": "https://finance.yahoo.com/markets/stocks/articles/aquestive-therapeutics-aqst-moves-6-113200077.html", "source_name": "Market source", "published_at": "2026-06-24T04:32:00", "published_display": "24 Jun 2026 04:32", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does US manufacturing give drugmakers a speed edge?", "summary": "Aquestive Therapeutics' quick resolution of an FDA rejection for Anaphylm, thanks to its U.S.-based manufacturing, highlights the speed advantages of domestic operations. This article explores how proximity to facilities can significantly cut down response times and complexities ", "url": "https://www.pharmavoice.com/news/us-pharma-manufacturing-pros-cons/823433/", "source_name": "Pharma Voice", "published_at": "2026-06-23T13:40:12", "published_display": "23 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST). The firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1180635", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T11:00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Aquestive Therapeutics, Inc. (AQST) regarding alleged corporate wrongdoing. The firm encourages Aquestive shareholders who purchased securities before June 16, 2025, and still hold them, to co", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aquestive-therapeu-1169387", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T11:00:00", "published_display": "21 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities before June 16, 2025, and continue to hold them. The firm is looking into possible corporate wrongdoing by Aquestive's ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1169386", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T16:09:54", "published_display": "19 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Aquestive Therapeutics Insiders Been Selling Stock?", "summary": "A recent analysis indicates that insiders at Aquestive Therapeutics (NASDAQ:AQST) have been selling stock, with CEO Daniel Barber divesting US$104k worth of shares, representing 3.8% of his holdings. This follows an earlier, larger sale of US$754k. Despite these sales, insiders s", "url": "https://www.sahmcapital.com/news/content/have-aquestive-therapeutics-insiders-been-selling-stock-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-18T16:09:54", "published_display": "18 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaWlBSUdLX01ETWd3QzBqQmxKWUdMSmlOMHc2WnRHd1hHR1N4ZGpTcHNtYVozNlc3UlNpOXFYZnJFdUk2amt1RXFMRTVPcE9pcld5QlM0NHBuOXpBTVZkNi00b1JiN0FOQjI0UjB3eVVhSmE5Z08tWjZxSXo0N2NEcEtPUlFxS0M3VC1aS2JjTzdvN1JKUHRPSWIwdnFSd2FsN085VlFmRlZIaVB1SjhiV0dLdW80MGV3U195ZTRn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQRHNKZWV5M0RJdk9JLVg4aXdhSjVKWDVyMjV2cXVxQWdzb0l6RXZnRWlZRlZBdEJKMkZSRGRCQUV3bk10WTlnMFROUVpHbHFYQk1CWnhZSEsxVXFuR2ZXa2d4RUsxUnN1WUg5enhUZUVRWk5USW5kUk1VcU8ybHFmNGsweDBhRVlDWGdveGdfbF9BYU1zOV9LV0diTVBNcHdXMmZGQ2ZB?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aquestive-therapeutics-inc-aqst-q1-230325069.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:03:25+00:00", "published_display": "14 May 2026 23:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/437fcac4-1696-345f-83f8-333585e4a64e/aquestive-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-14T14:07:38+00:00", "published_display": "14 May 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/aquestive-therapeutics-q1-earnings-snapshot-201020447.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:10:20+00:00", "published_display": "13 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQUDc1bkFlNlJXUnFEZmhUSElnR3lKT2JIejNJbTFRMzBLeUF6amZ6d3hmWXBKemZwOWNqVmR3NmJhT0xqcFpMYkJ0bGp5ck5VUzl4TFloODhEWHNRRnJ0aENVNG02b0o1MVg2RTVRbnA1MWhLdTBjS084SFYzUUhmUGNzNUFvSi15TjZjbW44R0c4QXdmZ004WDcyMjVVMWJ4VWt5RlF2d1BZWUowY0djRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbDdPR3RfVF9IRUVhVF9xRXRjVlJESnVReC1pY2lYSk13OV9DaVREM1hXYnpWcE1QbjVFYmFUWnNrUmxCWFZ5MjJZNXlNXzlBRzc4SWUwS2IxLVFpVVNqeEJ1aEdhZ1ZVSTBBckJUdWM3RjcyWWN0anhDZThpcVhfYzI0dl9XTHpXVks5aWswSlI4bll3ZmZHbE9yZGFiVjhrUU9KYWxoNDFFNGs?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNenprSXVaaWI1X2JsekpIV0RlVk9nT3p4OWw5bkJRNVpQaktUQVBCdmxPTmNIbUMzRHEtYXNkWFYtLWw0VW1Dck9UU1Y2SENTM3V1SWczUGpYbG5TTEZocDZfUnJXTERXbGRlMjJJU0ZISTNlbWtrY3hFenNjcDBFYWVoeTJPYW44RmpKSVFubnhoM0NnUW5oVEk5RkNlMmpNbFlqYUQ4YkJaX3FXTDBXcWt2c2VlVzUtcnR2S0xYbGJsb2x1RW1Ha0l1OGY5OENqU3gxbVNHcmFob1FldVZHS1RHYkcwd2plbkxJR19Rd3gtay15WXRya0pGZnc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTDJKdlZXYlBqN1c1NkFIYUZiQTRuRjlRZjYxLW9xY3BfWUxaR01IVDJOSGdHTm82R2VMZU05cldLczR6SnhxVi04eU95YXhuVTJTY2EyNEJaNUl0SGZDUXJOb2szWTl0dEhvZ1JhS0tBa2RXcTU0TExuLTJGRDNoMDV0Ykl1QUJjaVRIMHA4Vk1hX3FiaUh6S21CWHRfcGJ2Tnc5a3NxYmlKTXpXMk9tTUpR?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOeWVsU1hldVY1UWFkcU8tTnNxQzAtN25LamNzaXFmVHBjajBfaXRWNDlGVFJlc0t5VWxOYUo3WVIyMUVfcWFGYW0tN3ZFeWYtQjVBX285NzU0TEhaS19RZHhScE5jMUR3U29xRXNEbVZfZ3ZMYUs2VzNSZjUyWGtZOGNFRXV6d3VNSlBpNTNDQTBnRnZTQ1hzN25vRVE5Wm1lZ2R5XzdMR1pCcmNDdG9QWXI3UWx5TGhzTmtVTFF4cXk0MHBJckpTUkFuVmMxMUoxNDZCaElJalZJNGx4Z1dfNEpzMlh2RkZNOWdtMkNKdm1Tc0ZIS2NXRXF2Ukdqd28zLUxrSmxRMEhBWEQ4bjFFb1FVYzNRMDg?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics CEO Barber sells $753,965 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNX2JuVnlSbTFBNzlqQ0h3UWgtNlpaM0ZpTVVQZ0JGc3NUd0lFenhNWGFPRl9YTjBFMHA1RUhLZjlORVFza0JnX0h2T2c3WlAyRjBjYkhpOVlhQmlnOEdVOF9lX2VDOTk5NmZDQ3lJcDM2RmxSWDhXQ3I5LWt0UWhUSG02Z0JaRDhYM1FHbmZaX3Bham0zX3JqWEdJRkpxNnQ2S1JKOUlaUUNoRmg5WUpxQU9RVGlIZDdJb3poUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc. (AQST) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYUEwekpqbXRsVzhyVFFEaGRUU09DZkxab3l6Y3VPUi01TlNHNlk2Mm1GTVJsMDZFb2FJeU94NUdtWWdiRkJPUWhVUHo0MnlnMnZ5eWUwYVlPZ3N5LS1sUUI1VnNzWDBqR2RMekRtRjNGaHhmQWdYN0RZc3lRQ3BfSjh2OVJmMWJRNk1lNHM1clFFbjB4SE9pTXFhbjBQRktkMHRrRjlR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNbW9Fb1pUTUJYSVFjbnJ4LXoxZ2UtTGNwUE5HcmtYWGNTeXRpV1RfbEhFV0pCUTgwR01WV2dvOHRYSHhoN01ySTlhOGZvWTVVQ0txUzczWlhfeUFucDZfcW1Kck82OXBfNVNQLXpaYnI0aTVLSGJuRDJwNkJoaE1JQmRQS1VLZGlJVEpxanA1NmJNdlFSblpJNHhDTUpwZjRhSWhqN0RxNA?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Aquestive's oral drug for allergic reactions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOVFZyNUVKbFc2LXUxYWE2VVVCRl9mXzJXdWh4VENUTE1IWU54LWtCcjZYb2pLdVZnbjRsVmdINDBDbkpWRndVU252ZmUxSDZoSWN6TmM5TTJCUWcwRjBBLWpxUnE1V2k3dmMtNUZHajhzbnJCM2FfLW5aa0xFQ3hnSk9HZFA0Y1N0czhIWXV2Z3RwZllQLWtjSnV5ZTZETzI5bFp4aURkM0NhSnRiZmdxMHNON3dtR2s3U3RvdmV6LWRxRGZmRnVkY1NDTFZkQXc1?oc=5", "source_name": "Reuters", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVEYwR3BSLTVfdm8zNlczTVk5Q3htWjZfSFhoVDgyWjNQOE8tejJHV0JBeHJNak9WNG9URl85OTIwcHhBUlh1M3lCMFdVUGZPQ3QtR1JJVk55dlNjTWx1U0JLZFU5U0dkSGdCY21tUldVVTJ6c3dhUHVYNXJUSFJZeDV2QklvZEVESWFN?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. Common Stock AQST ) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBZOXJpdTk5MjhBTnZvMS14RExvTnpEQ04yYmdUcG5keHpuT3ZsNE1UX0pzYjhQZGpYal9BYzJfOGJSSzBPWUJEdXV3NkRyN1BPbDA1TUFJZw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:29:22+00:00", "published_display": "13 Jan 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxON2dYN1VBdDR3eW5lU3NUSEhFTmhwdU5oWWJ2U3pHdUliOWRyQ21zR3AySWg3Sm8wTGJIVjFpMFFscjM4VFN1RmYtUTlHRGY2VHZCaktfclFhVXVuendtcFJEMUZaSEd3bE15ODZOVzFDdlFyUE1FcHRqTlJIOWtIOGJwVG84XzZ1akxsbXIwUUYxak9tbU4tbFhmZFVTS2VKSDBuMkRSUWhHUlprMncw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE02VnVydzFLUzVXYU5DZVU0U2tuLVhVd3BMQ0hwSkNpRlNlMGt3eEZHM01Ia2RKdWdvOHJSX2ZiWmVoN0w3QkY3ZkMtY29KNS0tblBkcW9mb29idWZnX2tUY2g3OUI4ZmFPbXRyZnhJYTEtYkstT3c?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm Filing - What's Changed", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVXFmLWNsLU9qUGlReGVqTFZobUluM0RsS0xsN1YwYUFvQXRzTzQ0STNvNlBxZWhDcXBNMDZnRm8yX3Z5LUk2OVFmWWdjMlFVRFdETnhwX010UVdCUUxTSS1yR25yeWdHM1FLQzBPX3lCa3U2Mk5jS1NSQ3JmaUQxcDVnRVdmb1JRckdpd0Y4dGF6TlRwMHktbw?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice | AQST Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPd1NPSjlsanBIREVxbWtOTWxkdGVZX0lFSldUeW1kdlBSc0psNjctQ0FyT25tWi1sRll6MTdzX0ctMDBvRzlWcHFhT3JDTXF5aVd5UnczSThJTXlQQlFGU2lnUE9Vbm1EcUlRWXotSVBBSVJBSkptT0hRelpLSzhzMl9BUXdRdXVLUVVnMXVvLTFjYldVY3hFeXB1bUJ0Mi1WYXlkVUNKVUNmUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven On The Horizon For Aquestive Therapeutics, Inc. (NASDAQ:AQST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQTkZCWDdsUVhmM0Y5cmZRSkE5NFA1TWJHcmhlc0w2TG95M0s4ZEc2ODNYTlVTMVp3UzBYTVJlUy1pQ0dxaEVWV2dIZm1hRGlabXFEcm13R3hEN05Od2NMUVdJanZsU1BHWnhiSDBwSlBLSGNUY3BYSzlkVGY5T0otTEZXS1FLbzg0dXFuUERxd2dGejlr?oc=5", "source_name": "Market source", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer on Aquestive Therapeutics: \u201cI Think It\u2019s a Very Interesting Spec\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQZC12OEM1SFpZV3Rnd2lacWRyOGFtNUlfMUVZWFJoUlRnRmFpMVhGWHVCYlJYS0JMeXo2ZXVVMXUzaWVpNG9xRGEtR0JZaVRFU19USGlmaXptckd2TlhlVjF1OTNyc0dKcWJvYVJNamxJSjZkUzNpQ1RXcnV4a19jVnZhTHJMeWFwa2hNN3JB?oc=5", "source_name": "Market source", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Aquestive Therapeutics Stock Jumped After-Hours Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSkJqSDdZWFlkaThOWDdnSmZxdnl5c2pFcVVCU3IxX2Q4MExMRUZmdGZVQ3l1azA0cFJvMGJYQ0cwa0pjLS1kRU1SeUpCMjRmNkN2RUxiRGZReGF4NTd0M3FmejUxdlNrU3lRWEFrNzZXT0FfN0VvS21GV2tkY1BhQUloNVF1Q0kyUGRYWk9EdW9jX3ZJM0lSM01qQkJDdkF1VUpYdHkzOUdMQl9pTHl4eVhGYlhPRGhCMUd3MnFBOXlFbDF6d3o5RDE0MkJCTk9XZnlNVi1FV1Z4MzM2bk1WYnFNMDktN0ZZd254RWZB?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 144 Aquestive Therapeutics For: 15 July By Investing.com", "summary": "This article from Investing.com announces a Form 144 filing for Aquestive Therapeutics on July 15. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates of Aquestive Therapeutics plan to sell shares. The brief piece provides limi", "url": "https://ca.investing.com/news/stock-market-news/form-144-aquestive-therapeutics-for-15-july-93CH-4736181", "source_name": "Investing.com Canada", "published_at": "2026-07-16T01:45:38", "published_display": "16 Jul 2026 01:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aquestive Therapeutics, Inc. \u2013 NASDAQ:AQST", "summary": "This article provides financial information for Aquestive Therapeutics, Inc. (NASDAQ: AQST), specifically focusing on its forward price-to-earnings ratio. It is presented on TradingView, a platform offering various financial tools and market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T17:45:38", "published_display": "15 Jul 2026 17:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and cont", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1180644", "source_name": "ACCESS Newswire", "published_at": "2026-07-14T11:00:00", "published_display": "14 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc (AQST) Institutional Confidence", "summary": "Aquestive Therapeutics Inc (AQST) has an institutional shareholding score of 5.00, placing it 73rd in the Pharmaceuticals industry. Institutional investors collectively hold 60.30% of the company's shares, an increase of 16.75% quarter-over-quarter. Bill Nygren of OAKMX is the la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-aqst/sentiment", "source_name": "TradingKey", "published_at": "2026-07-13T13:43:38", "published_display": "13 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST) and its officers. The firm is encouraging shareholders who purchased AQST securities before June 16, 2025, and still hold them, to contact t", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aquestive-therapeutics-inc.-aqst-investigation-bronstein-gewirtz-1180643", "source_name": "ACCESS Newswire", "published_at": "2026-07-13T02:10:30", "published_display": "13 Jul 2026 02:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) concerning possible corporate wrongdoing by its officers and/or directors. The firm encourages investors who purchased Aquestive securities before June 16, 2025, and s", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1180642", "source_name": "ACCESS Newswire", "published_at": "2026-07-10T06:09:40", "published_display": "10 Jul 2026 06:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism", "summary": "Aquestive Therapeutics, a pharmaceutical company, will attend the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 14, 2026, where its management team will host 1x1 investor meetings. The forum will focus on key therapeutic themes in immunology, inflammation, and m", "url": "https://investingnews.com/aquestive-therapeutics-to-participate-in-leerink-partners-therapeutics-forum-ii-and-metabolism/", "source_name": "Investing News Network", "published_at": "2026-07-07T12:39:33", "published_display": "07 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) securities who bought prior to June 16, 2025, and still hold them. The investigation focuses on whether Aquestive and its officers/directors engaged", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aquestive-therapeu-1180641", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Aquestive Therapeutics (AQST)", "summary": "This article analyzes the historical performance of an imagined $1,000 investment in Aquestive Therapeutics (AQST) over one, five, and ten-year periods, showing the total returns and compound annual growth rates. It details Aquestive Therapeutics' business model, proprietary tech", "url": "https://www.stocktitan.net/tools/stock-return-calculator/AQST", "source_name": "Stock Titan", "published_at": "2026-07-04T00:09:48", "published_display": "04 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages Aquestive stockholders who purchased securities before June 16, 2025, and still hold them, to contact them for more information and to a", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1180639", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T02:41:21", "published_display": "02 Jul 2026 02:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to a", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aquestive-therapeutics-inc.-aqst-investigation-bronstein-gewirtz-1180638", "source_name": "ACCESS Newswire", "published_at": "2026-06-30T11:00:00", "published_display": "30 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Form S-3 filed by Aquestive Therapeutics Inc.", "summary": "Aquestive Therapeutics Inc. (AQST) filed an S-3 form with the SEC, which was promptly reported by Quantisnow. Quantisnow is a real-time market data and news platform that provides alerts on SEC filings, FDA approvals, analyst ratings, and insider trades to retail investors. The a", "url": "https://www.quantisnow.com/insight/sec-form-s-3-filed-by-aquestive-therapeutics-inc-6617429", "source_name": "Quantisnow", "published_at": "2026-06-27T19:41:22", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Aquestive Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on the filing of Form S-3 by Aquestive Therapeutics Inc. on June 26. The brief notice indicates a regulatory filing related to the company, suggesting potential corporate actions such as a stock offering.", "url": "https://ca.investing.com/news/stock-market-news/form-s3-aquestive-therapeutics-inc-for-26-june-93CH-4710049", "source_name": "Investing.com Canada", "published_at": "2026-06-26T20:40:55", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Stock Price and Chart \u2014 NASDAQ:AQST", "summary": "This page provides a comprehensive overview of Aquestive Therapeutics, Inc. (AQST) stock, including its current price, performance across various timeframes, key financial statistics, and upcoming earnings dates. It also features a collection of trading ideas and analyses from th", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:22", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. Actuals & Estimates (NASDAQ:AQST)", "summary": "This article provides an overview of Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock, including its current price, market capitalization, analyst forecasts, and historical performance. It also details recent financial actuals such as earnings per share and revenue, and forthcom", "url": "https://www.tradingview.com/symbols/NASDAQ-AQST/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:56", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9", "summary": "LifeSci Capital has reiterated its Buy rating for Aquestive Therapeutics (AQST.US) and maintained its target price at $9. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72051602/lifesci-capital-maintains-aquestive-therapeutics-aqstus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T01:12:46", "published_display": "26 Jun 2026 01:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether the company's officers and/or directo", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-aquestive-therapeutics-inc-aqst", "source_name": "The National Law Review", "published_at": "2026-06-25T15:10:52", "published_display": "25 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Aquestive Therapeutics Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Aquestive Therapeutics Inc. submitted on June 24th. The filing indicates insider transactions for the company (AQST). The article provides no further details beyond the existence of the filing and some financial data unrelated to the sp", "url": "https://ng.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-for-24-june-93CH-2572473", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T06:12:46", "published_display": "25 Jun 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics director Julie Krop sells $125k in stock By Investing.com", "summary": "Aquestive Therapeutics director Julie Krop sold $125,392 worth of company stock, involving 25,000 shares at $5.0157 per share, following the exercise of stock options. The sale was executed under a Rule 10b5-1 trading plan, occurring after the stock saw a 57% surge over the past ", "url": "https://ca.investing.com/news/stock-market-news/aquestive-therapeutics-director-julie-krop-sells-125k-in-stock-93CH-4705776", "source_name": "Investing.com Canada", "published_at": "2026-06-24T15:41:05", "published_display": "24 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?", "summary": "Aquestive Therapeutics (AQST) saw a 6.6% stock rally, closing at $5.03, driven by investor confidence in its lead product candidate, Anaphylm, and its development pipeline. The company plans to resubmit its NDA for Anaphylm in Q3 2026 and is also advancing AQST-108. Despite robus", "url": "https://finance.yahoo.com/markets/stocks/articles/aquestive-therapeutics-aqst-moves-6-113200077.html", "source_name": "Market source", "published_at": "2026-06-24T04:32:00", "published_display": "24 Jun 2026 04:32", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does US manufacturing give drugmakers a speed edge?", "summary": "Aquestive Therapeutics' quick resolution of an FDA rejection for Anaphylm, thanks to its U.S.-based manufacturing, highlights the speed advantages of domestic operations. This article explores how proximity to facilities can significantly cut down response times and complexities ", "url": "https://www.pharmavoice.com/news/us-pharma-manufacturing-pros-cons/823433/", "source_name": "Pharma Voice", "published_at": "2026-06-23T13:40:12", "published_display": "23 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aquestive Therapeutics, Inc. (AQST). The firm encourages investors who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1180635", "source_name": "ACCESS Newswire", "published_at": "2026-06-23T11:00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Aquestive Therapeutics, Inc. (AQST) regarding alleged corporate wrongdoing. The firm encourages Aquestive shareholders who purchased securities before June 16, 2025, and still hold them, to co", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aquestive-therapeu-1169387", "source_name": "ACCESS Newswire", "published_at": "2026-06-21T11:00:00", "published_display": "21 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities before June 16, 2025, and continue to hold them. The firm is looking into possible corporate wrongdoing by Aquestive's ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aquestive-th-1169386", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T16:09:54", "published_display": "19 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 26, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Aquestive Therapeutics Insiders Been Selling Stock?", "summary": "A recent analysis indicates that insiders at Aquestive Therapeutics (NASDAQ:AQST) have been selling stock, with CEO Daniel Barber divesting US$104k worth of shares, representing 3.8% of his holdings. This follows an earlier, larger sale of US$754k. Despite these sales, insiders s", "url": "https://www.sahmcapital.com/news/content/have-aquestive-therapeutics-insiders-been-selling-stock-2026-06-18", "source_name": "Sahm", "published_at": "2026-06-18T16:09:54", "published_display": "18 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNaWlBSUdLX01ETWd3QzBqQmxKWUdMSmlOMHc2WnRHd1hHR1N4ZGpTcHNtYVozNlc3UlNpOXFYZnJFdUk2amt1RXFMRTVPcE9pcld5QlM0NHBuOXpBTVZkNi00b1JiN0FOQjI0UjB3eVVhSmE5Z08tWjZxSXo0N2NEcEtPUlFxS0M3VC1aS2JjTzdvN1JKUHRPSWIwdnFSd2FsN085VlFmRlZIaVB1SjhiV0dLdW80MGV3U195ZTRn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQRHNKZWV5M0RJdk9JLVg4aXdhSjVKWDVyMjV2cXVxQWdzb0l6RXZnRWlZRlZBdEJKMkZSRGRCQUV3bk10WTlnMFROUVpHbHFYQk1CWnhZSEsxVXFuR2ZXa2d4RUsxUnN1WUg5enhUZUVRWk5USW5kUk1VcU8ybHFmNGsweDBhRVlDWGdveGdfbF9BYU1zOV9LV0diTVBNcHdXMmZGQ2ZB?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aquestive-therapeutics-inc-aqst-q1-230325069.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:03:25+00:00", "published_display": "14 May 2026 23:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/437fcac4-1696-345f-83f8-333585e4a64e/aquestive-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-14T14:07:38+00:00", "published_display": "14 May 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/aquestive-therapeutics-q1-earnings-snapshot-201020447.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:10:20+00:00", "published_display": "13 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQUDc1bkFlNlJXUnFEZmhUSElnR3lKT2JIejNJbTFRMzBLeUF6amZ6d3hmWXBKemZwOWNqVmR3NmJhT0xqcFpMYkJ0bGp5ck5VUzl4TFloODhEWHNRRnJ0aENVNG02b0o1MVg2RTVRbnA1MWhLdTBjS084SFYzUUhmUGNzNUFvSi15TjZjbW44R0c4QXdmZ004WDcyMjVVMWJ4VWt5RlF2d1BZWUowY0djRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbDdPR3RfVF9IRUVhVF9xRXRjVlJESnVReC1pY2lYSk13OV9DaVREM1hXYnpWcE1QbjVFYmFUWnNrUmxCWFZ5MjJZNXlNXzlBRzc4SWUwS2IxLVFpVVNqeEJ1aEdhZ1ZVSTBBckJUdWM3RjcyWWN0anhDZThpcVhfYzI0dl9XTHpXVks5aWswSlI4bll3ZmZHbE9yZGFiVjhrUU9KYWxoNDFFNGs?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNenprSXVaaWI1X2JsekpIV0RlVk9nT3p4OWw5bkJRNVpQaktUQVBCdmxPTmNIbUMzRHEtYXNkWFYtLWw0VW1Dck9UU1Y2SENTM3V1SWczUGpYbG5TTEZocDZfUnJXTERXbGRlMjJJU0ZISTNlbWtrY3hFenNjcDBFYWVoeTJPYW44RmpKSVFubnhoM0NnUW5oVEk5RkNlMmpNbFlqYUQ4YkJaX3FXTDBXcWt2c2VlVzUtcnR2S0xYbGJsb2x1RW1Ha0l1OGY5OENqU3gxbVNHcmFob1FldVZHS1RHYkcwd2plbkxJR19Rd3gtay15WXRya0pGZnc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTDJKdlZXYlBqN1c1NkFIYUZiQTRuRjlRZjYxLW9xY3BfWUxaR01IVDJOSGdHTm82R2VMZU05cldLczR6SnhxVi04eU95YXhuVTJTY2EyNEJaNUl0SGZDUXJOb2szWTl0dEhvZ1JhS0tBa2RXcTU0TExuLTJGRDNoMDV0Ykl1QUJjaVRIMHA4Vk1hX3FiaUh6S21CWHRfcGJ2Tnc5a3NxYmlKTXpXMk9tTUpR?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOeWVsU1hldVY1UWFkcU8tTnNxQzAtN25LamNzaXFmVHBjajBfaXRWNDlGVFJlc0t5VWxOYUo3WVIyMUVfcWFGYW0tN3ZFeWYtQjVBX285NzU0TEhaS19RZHhScE5jMUR3U29xRXNEbVZfZ3ZMYUs2VzNSZjUyWGtZOGNFRXV6d3VNSlBpNTNDQTBnRnZTQ1hzN25vRVE5Wm1lZ2R5XzdMR1pCcmNDdG9QWXI3UWx5TGhzTmtVTFF4cXk0MHBJckpTUkFuVmMxMUoxNDZCaElJalZJNGx4Z1dfNEpzMlh2RkZNOWdtMkNKdm1Tc0ZIS2NXRXF2Ukdqd28zLUxrSmxRMEhBWEQ4bjFFb1FVYzNRMDg?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics CEO Barber sells $753,965 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNX2JuVnlSbTFBNzlqQ0h3UWgtNlpaM0ZpTVVQZ0JGc3NUd0lFenhNWGFPRl9YTjBFMHA1RUhLZjlORVFza0JnX0h2T2c3WlAyRjBjYkhpOVlhQmlnOEdVOF9lX2VDOTk5NmZDQ3lJcDM2RmxSWDhXQ3I5LWt0UWhUSG02Z0JaRDhYM1FHbmZaX3Bham0zX3JqWEdJRkpxNnQ2S1JKOUlaUUNoRmg5WUpxQU9RVGlIZDdJb3poUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Inc. (AQST) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYUEwekpqbXRsVzhyVFFEaGRUU09DZkxab3l6Y3VPUi01TlNHNlk2Mm1GTVJsMDZFb2FJeU94NUdtWWdiRkJPUWhVUHo0MnlnMnZ5eWUwYVlPZ3N5LS1sUUI1VnNzWDBqR2RMekRtRjNGaHhmQWdYN0RZc3lRQ3BfSjh2OVJmMWJRNk1lNHM1clFFbjB4SE9pTXFhbjBQRktkMHRrRjlR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQNmxLbUdCekJ3bWtRNFo2bDZzTHpzeUs5ZjRCYWJYNHVUMWZuaE5mZE95TW5MRnVfMjlTMGdmOU5uTnQtUnFUOW1QQXVsY0t5RHpPTWw4WXR4WS1fbnp5MTQtM1hRR05DZ09la3JPV1BxcWZ2ZGNpcXhKQk5DMUdjLTZneEVYMFhtN3BzZkxIWUpsajgwRlFVR0M3UkwySDZLRGNOX0J4dTdQT2s0bXJVTkU5Y0JFVk9kYjVVUlFZUkttcGZMa1FKd1pZam5ad201aU5yNGxzcUdETFBsUVZaVGVMMXNlUjJhSmg2VtIB8gFBVV95cUxPS05ZN3c1Z0NXcTJDNzRvUG5tZjJBQm1ZVVR3WUlMTy1XUDN6S2pnVzBJTWJPOXYzZVp3d0lQaHRJOE94My00cVM1VHR5ajlqS0NRSFZDSzAtQm5IcnpfSTNKXy1TTjJLcUVjc0pORk1FdzNKQ1A4alQ5bGIxYWFDSDZPYW5aOUJYVWFXUHNPQjYzNVBuMC11cklTNTQwVHV2amNKWlpYTl9aOEZPdlZ2Z2k1MGNGUzBXdEdVYXpzVDJoUGNCMWVUbUdmRnlldUpXM1FRMjdHWHZPczJpX0FoQjhhMDExT2ZMX1A0VXJSNFhPdw?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNbW9Fb1pUTUJYSVFjbnJ4LXoxZ2UtTGNwUE5HcmtYWGNTeXRpV1RfbEhFV0pCUTgwR01WV2dvOHRYSHhoN01ySTlhOGZvWTVVQ0txUzczWlhfeUFucDZfcW1Kck82OXBfNVNQLXpaYnI0aTVLSGJuRDJwNkJoaE1JQmRQS1VLZGlJVEpxanA1NmJNdlFSblpJNHhDTUpwZjRhSWhqN0RxNA?oc=5", "source_name": "The American Journal of Managed Care\u00ae (AJMC\u00ae)", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Aquestive's oral drug for allergic reactions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOVFZyNUVKbFc2LXUxYWE2VVVCRl9mXzJXdWh4VENUTE1IWU54LWtCcjZYb2pLdVZnbjRsVmdINDBDbkpWRndVU252ZmUxSDZoSWN6TmM5TTJCUWcwRjBBLWpxUnE1V2k3dmMtNUZHajhzbnJCM2FfLW5aa0xFQ3hnSk9HZFA0Y1N0czhIWXV2Z3RwZllQLWtjSnV5ZTZETzI5bFp4aURkM0NhSnRiZmdxMHNON3dtR2s3U3RvdmV6LWRxRGZmRnVkY1NDTFZkQXc1?oc=5", "source_name": "Reuters", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVEYwR3BSLTVfdm8zNlczTVk5Q3htWjZfSFhoVDgyWjNQOE8tejJHV0JBeHJNak9WNG9URl85OTIwcHhBUlh1M3lCMFdVUGZPQ3QtR1JJVk55dlNjTWx1U0JLZFU5U0dkSGdCY21tUldVVTJ6c3dhUHVYNXJUSFJZeDV2QklvZEVESWFN?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics, Inc. Common Stock AQST ) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBZOXJpdTk5MjhBTnZvMS14RExvTnpEQ04yYmdUcG5keHpuT3ZsNE1UX0pzYjhQZGpYal9BYzJfOGJSSzBPWUJEdXV3NkRyN1BPbDA1TUFJZw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:29:22+00:00", "published_display": "13 Jan 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxON2dYN1VBdDR3eW5lU3NUSEhFTmhwdU5oWWJ2U3pHdUliOWRyQ21zR3AySWg3Sm8wTGJIVjFpMFFscjM4VFN1RmYtUTlHRGY2VHZCaktfclFhVXVuendtcFJEMUZaSEd3bE15ODZOVzFDdlFyUE1FcHRqTlJIOWtIOGJwVG84XzZ1akxsbXIwUUYxak9tbU4tbFhmZFVTS2VKSDBuMkRSUWhHUlprMncw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE02VnVydzFLUzVXYU5DZVU0U2tuLVhVd3BMQ0hwSkNpRlNlMGt3eEZHM01Ia2RKdWdvOHJSX2ZiWmVoN0w3QkY3ZkMtY29KNS0tblBkcW9mb29idWZnX2tUY2g3OUI4ZmFPbXRyZnhJYTEtYkstT3c?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm Filing - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOamViRE9DdS1WMDJJOXZnNHhzWVNGb2ZCX3FhdUFPTE9TdGlFaE5zQjhkaDkxcEhDaGc0M0xBRVl4ektXemJ0MzNYT19NTUctVXNxWjQ5eF9GUVBKQTlUSXBCWVJUbzY1SnYzMWp6RWg1MHdibjgxYzkwTURMT2xYQURCLXNSbXdjUVNPa0tnMWRfQkNKejhlNHByQUVpVENVUHVIRmo2eGVnN3I0OEdOZkQzZFRuYWJSekMyQ081ZXYzTmp3NkQzb0pvMDRFVjAtRXBRTWVpUEVCTlpBRFZOWUdPb042bWdGRk5pWNIB8gFBVV95cUxQWXNmS1prX3ltYXZRRTJHVHp3VHZJckE0cnJsVjNicXNudDFOZE5lc0g3SzBsb1BqMmluOWdKNnBMNFFmR21OZjdUWGV1WG9nZTR4MnI4QWFfRzJlX0RucTQyNTVLc0c2elhGRThzS2RENlZBWFE1YWNrWHczYjdmVUE0N1RrUEJJd0NFVnRraHBWUndtc3dCeHBwR0pkRVJuVFExZjRfcVBzMHRtNXlqZHNCZW1NOHZ2VHpBT1g4cGxSVHdIS1Y1T2VIVXlWQU04bzEtdGZJS0dQWnZVdm82YUNqcGwxeEliQ3dBT1Z3QkEyQQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVXFmLWNsLU9qUGlReGVqTFZobUluM0RsS0xsN1YwYUFvQXRzTzQ0STNvNlBxZWhDcXBNMDZnRm8yX3Z5LUk2OVFmWWdjMlFVRFdETnhwX010UVdCUUxTSS1yR25yeWdHM1FLQzBPX3lCa3U2Mk5jS1NSQ3JmaUQxcDVnRVdmb1JRckdpd0Y4dGF6TlRwMHktbw?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice | AQST Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPd1NPSjlsanBIREVxbWtOTWxkdGVZX0lFSldUeW1kdlBSc0psNjctQ0FyT25tWi1sRll6MTdzX0ctMDBvRzlWcHFhT3JDTXF5aVd5UnczSThJTXlQQlFGU2lnUE9Vbm1EcUlRWXotSVBBSVJBSkptT0hRelpLSzhzMl9BUXdRdXVLUVVnMXVvLTFjYldVY3hFeXB1bUJ0Mi1WYXlkVUNKVUNmUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven On The Horizon For Aquestive Therapeutics, Inc. (NASDAQ:AQST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQTkZCWDdsUVhmM0Y5cmZRSkE5NFA1TWJHcmhlc0w2TG95M0s4ZEc2ODNYTlVTMVp3UzBYTVJlUy1pQ0dxaEVWV2dIZm1hRGlabXFEcm13R3hEN05Od2NMUVdJanZsU1BHWnhiSDBwSlBLSGNUY3BYSzlkVGY5T0otTEZXS1FLbzg0dXFuUERxd2dGejlr?oc=5", "source_name": "Market source", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer on Aquestive Therapeutics: \u201cI Think It\u2019s a Very Interesting Spec\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQZC12OEM1SFpZV3Rnd2lacWRyOGFtNUlfMUVZWFJoUlRnRmFpMVhGWHVCYlJYS0JMeXo2ZXVVMXUzaWVpNG9xRGEtR0JZaVRFU19USGlmaXptckd2TlhlVjF1OTNyc0dKcWJvYVJNamxJSjZkUzNpQ1RXcnV4a19jVnZhTHJMeWFwa2hNN3JB?oc=5", "source_name": "Market source", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Aquestive Therapeutics Stock Jumped After-Hours Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSkJqSDdZWFlkaThOWDdnSmZxdnl5c2pFcVVCU3IxX2Q4MExMRUZmdGZVQ3l1azA0cFJvMGJYQ0cwa0pjLS1kRU1SeUpCMjRmNkN2RUxiRGZReGF4NTd0M3FmejUxdlNrU3lRWEFrNzZXT0FfN0VvS21GV2tkY1BhQUloNVF1Q0kyUGRYWk9EdW9jX3ZJM0lSM01qQkJDdkF1VUpYdHkzOUdMQl9pTHl4eVhGYlhPRGhCMUd3MnFBOXlFbDF6d3o5RDE0MkJCTk9XZnlNVi1FV1Z4MzM2bk1WYnFNMDktN0ZZd254RWZB?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 86, "total_relevant": 55, "sentiment_summary": {"positive": 8, "negative": 17, "neutral": 30, "score": 45, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.4, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.4, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.0, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 4.12, "latest_week": "2026-07-10", "one_week_move": -1.4, "four_week_move": -1.2, "twelve_week_move": -4.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.652143, "market_dynamics_buy_signal": false, "relative_strength": -25.564772, "fair_value_gap": 12.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.0721, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.4% over one week, -1.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "ACCESS Newswire", "count": 9}, {"label": "simplywall.st", "count": 6}, {"label": "Investing.com Canada", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 11}, {"label": "Analyst action", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "45/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.4% over one week, -1.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 144 Aquestive Therapeutics For: 15 July By Investing.com"}], "updated_at": "2026-07-16T11:59:38.304903+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}